These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15841447)

  • 1. Homocysteine, the bad thiol.
    Mato JM; Lu SC
    Hepatology; 2005 May; 41(5):976-9. PubMed ID: 15841447
    [No Abstract]   [Full Text] [Related]  

  • 2. Homocysteine toxicity in connective tissue: theories, old and new.
    Toohey JI
    Connect Tissue Res; 2008; 49(2):57-61. PubMed ID: 18382890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperhomocysteinemia and changed plasma thiol redox status in chronic obstructive pulmonary disease.
    Andersson A; Ankerst J; Lindgren A; Larsson K; Hultberg B
    Clin Chem Lab Med; 2001 Mar; 39(3):229-33. PubMed ID: 11350020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homocysteinemia correlates with plasma thiol redox status in patients with end-stage renal disease.
    Palleschi S; De Angelis S; Rossi B; Diana L; Papa V; Severini G; Splendiani G
    Nephron Clin Pract; 2008; 108(2):c106-12. PubMed ID: 18212512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reconsideration of homocysteinemia].
    Ishii I
    Seikagaku; 2013 Dec; 85(12):1067-71. PubMed ID: 24505936
    [No Abstract]   [Full Text] [Related]  

  • 6. Homocysteine thiolactone-induced hyperhomocysteinemia does not alter concentrations of cholesterol and SREBP-2 target gene mRNAS in rats.
    Stangl GI; Weisse K; Dinger C; Hirche F; Brandsch C; Eder K
    Exp Biol Med (Maywood); 2007 Jan; 232(1):81-7. PubMed ID: 17202588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hyperhomocysteinemia as a clinical manifestation of thrombosis risk].
    Kozlova TV
    Klin Med (Mosk); 2005; 83(2):9-12. PubMed ID: 15803823
    [No Abstract]   [Full Text] [Related]  

  • 8. [Sulfhydryl and disulfide compounds in serum proteins of normal subjects and in patients with liver and kidney diseases].
    Kaplanskii SIa; Aziavchik AV
    Vopr Med Khim; 1965; 11(2):41-6. PubMed ID: 5885694
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanisms of homocysteine toxicity in humans.
    Perła-Kaján J; Twardowski T; Jakubowski H
    Amino Acids; 2007; 32(4):561-72. PubMed ID: 17285228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperhomocysteinemia induces a tissue specific accumulation of homocysteine in bone by collagen binding and adversely affects bone.
    Herrmann M; Tami A; Wildemann B; Wolny M; Wagner A; Schorr H; Taban-Shomal O; Umanskaya N; Ross S; Garcia P; Hübner U; Herrmann W
    Bone; 2009 Mar; 44(3):467-75. PubMed ID: 19056526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homocysteine in microvascular endothelial cell barrier permeability.
    Tyagi SC; Lominadze D; Roberts AM
    Cell Biochem Biophys; 2005; 43(1):37-44. PubMed ID: 16043881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocysteine and coronary microcirculation: is it a microvasculopathic agent?
    Turhan H; Aksoy Y; Yetkin E
    Int J Cardiol; 2006 Jun; 110(2):269-70. PubMed ID: 16325281
    [No Abstract]   [Full Text] [Related]  

  • 13. [Advances in studies on the protein homocysteinylation].
    Li J; Feng J; Wang X
    Sheng Li Ke Xue Jin Zhan; 2011 Aug; 42(4):291-5. PubMed ID: 22066422
    [No Abstract]   [Full Text] [Related]  

  • 14. Homocysteine and brain atrophy.
    Sachdev PS
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Sep; 29(7):1152-61. PubMed ID: 16102882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental hyperhomocysteinemia impairs coronary flow velocity reserve.
    Yamashita K; Tasaki H; Nagai Y; Suzuka H; Nihei S; Kobayashi K; Horiuchi M; Nakashima Y; Adachi T
    Int J Cardiol; 2005 Sep; 104(2):163-9. PubMed ID: 16168809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of copper is a mechanism of homocysteine toxicity leading to COX deficiency and apoptosis in primary neurons, PC12 and SHSY-5Y cells.
    Linnebank M; Lutz H; Jarre E; Vielhaber S; Noelker C; Struys E; Jakobs C; Klockgether T; Evert BO; Kunz WS; Wüllner U
    Neurobiol Dis; 2006 Sep; 23(3):725-30. PubMed ID: 16876425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of erythrocyte sensitivity to oxidative stress by transient hyperhomocysteinemia in healthy subjects and in patients with coronary artery disease.
    Vesentini N; Kusmic C; Battaglia D; Taddei MC; Barsanti L; Parodi O; Palombo C; Paolicchi A; Barsacchi R
    Nutr Metab Cardiovasc Dis; 2008 Jul; 18(6):402-7. PubMed ID: 18029159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondrial mechanism of oxidative stress and systemic hypertension in hyperhomocysteinemia.
    Tyagi N; Moshal KS; Ovechkin AV; Rodriguez W; Steed M; Henderson B; Roberts AM; Joshua IG; Tyagi SC
    J Cell Biochem; 2005 Nov; 96(4):665-71. PubMed ID: 16149054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ras proteins, nitrosylation and homocysteine metabolism.
    Mikeladze D; Zhuravliova E; Barbakadze T
    Georgian Med News; 2008 Sep; (162):30-3. PubMed ID: 18830027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia.
    Sauls DL; Arnold EK; Bell CW; Allen JC; Hoffman M
    Thromb Res; 2007; 120(1):117-26. PubMed ID: 16979225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.